We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Hatch, Waxman Signal Concern About "Authorized Generics"

Law360 (October 10, 2004, 12:00 AM EDT) -- The authors of the Hatch-Waxman Act signaled their concern about the growing popularity of so-called “authorized generics” agreements at an industry conference last week, warning that the issue is serious enough to warrant congressional examination.

During a two-day Drug & Device Dialogue conference called “Following On Hatch-Waxman: Credentials for Success,” Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) hinted the impact of authorized generics on competition in the pharmaceutical sector is undermining the principles of the Hatch-Waxman Act.

"I think that's certainly an area that...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.